CHF6001

DRUG4 trials

Sponsors

Chiesi Farmaceutici S.p.A.

Conditions

AsthmaCOPDChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)

Phase 1

Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects

CompletedNCT04756960

Chiesi Farmaceutici S.p.A.Chronic Obstructive Pulmonary Disease (COPD), COPD

Start: 2021-03-10End: 2021-04-29Updated: 2024-03-18

Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects

CompletedNCT05373953

Chiesi Farmaceutici S.p.A.Chronic Obstructive Pulmonary Disease

Start: 2022-05-05End: 2022-11-25Updated: 2024-04-15

Phase 2

A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics

CompletedNCT01689571

Chiesi Farmaceutici S.p.A.Asthma

Start: 2012-10-31End: 2013-04-30Updated: 2017-03-30

A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD

CompletedNCT02986321

Chiesi Farmaceutici S.p.A.Chronic Obstructive Pulmonary Disease

Start: 2016-12-15End: 2018-01-09Updated: 2019-01-28

Related Papers

Evaluating the Impact of Hepatic or Renal Impairment on Tanimilast (<scp>CHF6001</scp>) Pharmacokinetics: Two Open‐Label, Parallel‐Group, Single‐Center Studies

Clinical and Translational Science2025-05-01

Serum IL-8 as a Determinant of Response to Phosphodiesterase-4 Inhibition in Chronic Obstructive Pulmonary Disease

American Journal of Respiratory and Critical Care Medicine2023-05-168 citations

Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study

Respiratory Research2020-09-2245 citations